Abstract

The approval of CD19 chimeric antigen receptor (CAR)-engineered T (CAR-T) cell products in B-cell malignancies represents a breakthrough in CAR-T cell immunotherapy. However, the remaining limitations concerning the graft-versus-host disease (GVHD) and other adverse effects (e.g., cytokine release syndromes [CRS] and neurotoxicity) still restrict their wider applications. Natural killer (NK) cells have been identified as promising candidates for CAR-based cellular immunotherapy because of their unique characteristics. No HLA-matching restriction and abundant sources make CAR-engineered NK (CAR-NK) cells potentially available to be off-the-shelf products that could be readily available for immediate clinical use. Therefore, researchers have gradually shifted their focus from CAR-T cells to CAR-NK cells in hematological malignancies. This review discusses the current status and applications of CAR-NK cells in hematological malignancies, as well as the unique advantages of CAR-NK cells compared with CAR-T cells. It also discusses challenges and prospects regarding clinical applications of CAR-NK cells.

Highlights

  • Hematological malignancies, which contribute to approximately 7% of all newly diagnosed cancers, represent a class of malignant clonal diseases originating in the hematopoietic system, mainly including leukemia, lymphoma and multiple myeloma (MM) [1, 2]

  • Despite considerable progress in chimeric antigen receptor (CAR)-T cell-based immunotherapy for patients with blood diseases, there remain restrictions that inhibit its broader application in future treatment of hematological malignancies: [1] CRS and neurotoxicity are notable acute side effects that occur during CD19 CAR-T cell therapy [12]; [2] on-target off-tumor effects may occur related to the recognition of molecular biomarkers that are expressed on healthy tissues (e.g., B cell aplasia in anti-CD19/CD20 CAR-T cell therapy) [13]; [3] antigen escape/ loss may lead to disease relapse [14]; [4] life-threatening graft-versus-host disease (GVHD) may be caused by allogeneic CAR-T cells [15]; [5] restrictions concerning inclusion in commercialized and “off-the-shelf” products have been implemented because of the HLA restriction and insufficient sources of T cells

  • The emergence of CAR-T cells is a breakthrough in cancer immunotherapy, especially for B-cell malignancies

Read more

Summary

INTRODUCTION

Hematological malignancies, which contribute to approximately 7% of all newly diagnosed cancers, represent a class of malignant clonal diseases originating in the hematopoietic system, mainly including leukemia, lymphoma and multiple myeloma (MM) [1, 2]. Immunotherapy (e.g., cytokine therapy, immune checkpoint blockade, and CAR-T cell therapy) has enriched treatment methods and improved the prognosis of patients with hematological tumors [3, 6]. Transfusion of NK cells is an effective adoptive immunotherapy method to improve the number and the function of NK cells [30] These approaches used for NK cell therapy are applicable for CAR-NK cell therapy. Similar to the structures of CAR-T cells, CAR-NK cells are composed of CARs (genetically engineered transmembrane receptors) and effector cells (NK cells)

CAR Constructs
NK Cells
NK cell sources
Multiple Myeloma
Findings
CONCLUSIONS
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call